Making best use of bone turnover markers to monitor oral bisphosphonate therapy

Cleve Clin J Med. 2023 Jan 3;90(1):32-34. doi: 10.3949/ccjm.90a.22092.

Author

Affiliation

¹ Staff Rheumatologist, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH kellers@ccf.org.

PMID: 36596599
DOI: 10.3949/ccjm.90a.22092

No abstract available

Publication types

Editorial
Comment

MeSH terms

Administration, Oral
Biomarkers
Bone Density
Bone Density Conservation Agents* / adverse effects
Bone Remodeling
Diphosphonates* / adverse effects
Humans

Substances

Diphosphonates
Bone Density Conservation Agents
Biomarkers